This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
Home
Products
Rezurock®▼ (belumosudil) tablets (GB ONLY)

REZUROCK® 

(belumosudil) tablets

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

REZUROCK is recommended by NICE, within its marketing authorisation, for treating chronic graft-versus-host disease (chronic GVHD) in people 12 years and older after 2 or more systemic treatments.6

Profile

REZUROCK is indicated for the treatment of  patients aged 12 years old or older with chronic GVHD who have recieved at least two prior lines of systemic therapy.1

REZUROCK targets both the inflammatory and fibrotic processes of cGVHD through selective inhibition of the ROCK2 pathway.1-3

REZUROCK demonstrated efficacy in a broad range of patients with cGVHD.4

The safety profile of REZUROCK was evaluated across 2 multicenter clinical studies.4-5

1/3

REZUROCK targets both the inflammatory and fibrotic processes of cGVHD through selective inhibition of the ROCK2 pathway.1-3

REZUROCK demonstrated efficacy in a broad range of patients with cGVHD.4

The safety profile of REZUROCK was evaluated across 2 multicenter clinical studies.4-5

SEE MORE FROM SCIENCE

Eligibility for REZUROCK

When any 2 prior lines of systemic therapy fail, consider REZUROCK.1

patient profiles image

 

Explore patient profiles eligible for REZUROCK after failure of any 2 prior lines of systemic therapy.

Dosing and Administration

A once-daily oral tablet for patients with cGVHD.1

  • Do not store REZUROCK above 25°C.
  • Each pale-yellow, oblong, 200-mg tablet is debossed with "KDM" on one side and “200” on the other side, with dimensions of 7.40x14.77mm.1 
  • REZUROCK should be dispensed to the patient in the original container only. Store in original container to protect from moisture. Replace cap securely each time after opening. Do not discard desiccant.1

Please refer to the full Summary of Product Characteristics before prescribing.

Patient Support 

Printer-Friendly Guide

print-version (1).png

Suitable for those who prefer a physical copy or want to keep it handy.

Mobile-Friendly Guide

mobile-version (1).png

Optimal for convenient access on mobile devices.

Mechanism of Action

How REZUROCK works

This video describes how REZUROCK targets both the inflammatory and fibrotic processes of cGvHD through selective inhibition of the ROCK2 pathway.1-3

Get in touch with the Transplant Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References

  1. REZUROCK. Summary of Product Characteristics

  2. Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814-16819. doi:10.1073/pnas.1414189111

  3. Flynn R, Paz K, Du J, et al. Targeted rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144-2154. doi:10.1182/blood-2015-10-678706

  4. Cutler C, Lee SJ, Arai S. et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138(22):2278-2289. doi: 10.1182/blood.2021012021

  5. Jagasia M, Lazaryan A, Bachier CR. et al. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021;39(17):1888-1898. doi: 10.1200/JCO.20.02754

  6. NICE. Technology appraisal guidance TA949. https://www.nice.org.uk/guidance/TA949. Last accessed: February 2024

MAT-XU-2305107 (v2.0) Date of Preparation: March 2024